Pretax income is the income that a company earns before paying income taxes. Neurocrine Biosciences's pretax income for the
three
months ended in Dec. 2023 was $198 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $332 Mil.
Neurocrine Biosciences's pretax margin was 38.47%.
During the past 13 years, Neurocrine Biosciences's highest Pretax Margin was 17.60%. The lowest was -940.60%. And the median was 5.90%.
Neurocrine Biosciences Pre-Tax Income Historical Data
The historical data trend for Neurocrine Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neurocrine Biosciences's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Pre-Tax Income falls into.
Neurocrine Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Neurocrine Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $332 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (NAS:NBIX) Pre-Tax Income Explanation
Neurocrine Biosciences's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Neurocrine Biosciences's highest Pretax Margin was 17.60%. The lowest was -940.60%. And the median was 5.90%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Neurocrine Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Neurocrine Biosciences (Neurocrine Biosciences) Business Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBIX has been successfully added to your 